SCHEMBL15969299

SCHEMBL15969299

O=C1CN=C(c2ccc(OCc3ccccc3)c(F)c2)O1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.44
S1PR5 Q9H228 1/20 0.42
GRM2 Q14416 1/20 0.42
CTSA P10619 1/20 0.42
PRMT5 O14744 1/20 0.41
CTSV O60911 1/20 0.40
CTSL P07711 1/20 0.40
SLK Q9H2G2 2/20 0.39
STK10 O94804 1/20 0.39
MAOB P27338 1/20 0.39
MRGPRX4 Q96LA9 3/20 0.38
FFAR1 O14842 1/20 0.38
PPARD Q03181 1/20 0.38
SCN9A Q15858 1/20 0.38
KDM1A O60341 2/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15986957 0.80 THRA (0.39) S1PR5GRM2
SCHEMBL21162496 0.71 ERN1 (0.59) ERN1S1PR5CTSAMRGPRX4FFAR1
SCHEMBL8993210 0.71 ERN1 (0.56) ERN1S1PR5CTSAMRGPRX4FFAR1
SCHEMBL8619252 0.71 ERN1 (0.53) ERN1S1PR5CTSAMAOBFFAR1
SCHEMBL8617145 0.71 ERN1 (0.53) ERN1S1PR5CTSAMAOBFFAR1
SCHEMBL24363273 0.70 ERN1 (0.50) ERN1S1PR5GRM2CTSAPRMT5
SCHEMBL27756228 0.70 ERN1 (0.50) ERN1S1PR5GRM2CTSAPRMT5
SCHEMBL8993237 0.70 ERN1 (0.58) ERN1S1PR5CTSAMRGPRX4FFAR1
SCHEMBL8612029 0.70 ERN1 (0.52) ERN1S1PR5CTSAMRGPRX4FFAR1
SCHEMBL10093047 0.70 ERN1 (0.55) ERN1S1PR5GRM2CTSAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963043-B1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2018-05-30 EP disclosed
EP-2963043-B1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2018-05-30 EP disclosed
US-9458176-B2 Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-04 US disclosed
EP-2963043-A1 TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2016-01-06 EP disclosed
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243316-A1 Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative GRM2, GRM1, GRIA2 ERN1 4184/4885S1PR5 1037/4885GRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.